


Non-Hodgkin's Lymphoma Drives The Rituximab Biosimilars Industry

*The Business Research Company's
Rituximab Biosimilars Global Market
Report 2020-30: COVID-19 Growth and
Change*

LONDON, GREATER LONDON, UK,
February 8, 2021 /EINPresswire.com/ --

New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact:

<https://www.thebusinessresearchcompany.com/global-market-reports>



The rising prevalence of non-Hodgkin's lymphoma (NHL) is predicted to contribute to the [growth of the rituximab biosimilars market](#). Non-Hodgkin's lymphoma is a cancer that starts in white blood cells (lymphocytes) that are part of the body's immune system. In 2018, rituximab-abbs was approved as the first rituximab biosimilars for the treatment of patients with B-cell NHL and adult patients with CD20-positive. According to the National Library of Medicine's statistics, non-Hodgkin lymphoma was ranked as the 5th to 9th most common cancers in most of the countries, with approximately 5,10,000 new cases in 2018, globally. Moreover, according to the American Cancer Society, NHL is the most common cancer in the USA. About 77,240 people (34,860 females and 42,380 males) are estimated to be diagnosed with NHL by the end of 2020 in the USA. Thus, growing cases of non-Hodgkin's lymphoma are predicted to generate high demand for rituximab biosimilars over the forecast period.

The global [rituximab biosimilars market](#) was expected to decline from \$1.84 billion in 2019 to \$1.78 billion in 2020 at a compound annual growth rate (CAGR) of -3.22%. The decline was mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is expected to recover and reach \$2.62 billion in 2023 at a CAGR of 13.85%. Europe accounts for the largest rituximab biosimilars market share, while Asia-Pacific is

expected to be the fastest-growing region in the forecast period.

Here Is A List Of Similar Reports By The Business Research Company:

Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/oncology-drugs-market>

CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/car-t-therapy-market>

Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth And Change

<https://www.thebusinessresearchcompany.com/report/cancer-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change>

Interested to know more about [The Business Research Company?](#)

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/535327485>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.